Thyroid News and Research

RSS

Organic pollutants in flame retardents cause molecular changes in reproductive organs

Polybrominated diphenyl ethers (PBDEs) are chemicals that have been widely used as flame retardants and are now classified as persistent organic pollutants. Health concerns in humans have arisen based primarily on studies with laboratory animals exposed to high levels of PBDEs. Three commercial mixtures of PBDEs have been manufactured in or imported into the United States which include penta-, octa-, and deca-brominated diphenyl ethers (BDEs).

15 Apr 2011

Study finds minimally invasive thyroid surgery effective in pediatric patients

Surgical approaches that reduce incision size and recovery time from thyroid surgery work well in children, physician-scientists report.

15 Apr 2011

New research suggests iodine-deficiency in large UK population

New research suggests the UK population is now iodine-deficient and a full review and evidence-based recommendations are needed to safeguard public health.

12 Apr 2011

Research on rare cancers

A cancer diagnosis can be a life-changing event. Many questions arise, with one of the first being, "Where should I be treated?" Patients diagnosed with rare cancers may have difficulty finding a physician knowledgeable in treating their type of cancer.

11 Apr 2011

New ATA recommendations on outpatient 131I therapy aim to treat thyroid cancer

New recommendations from the American Thyroid Association on outpatient radioiodine treatment aim to minimize unintended radiation exposure and maximize the safety of patients, their families, and the public.

8 Apr 2011

Genzyme's alemtuzumab Phase 2 trial data in MS to be presented at AAN meeting

Genzyme, a subsidiary of sanofi-aventis Group, announced today that it will present new data from its completed Phase 2 trial of the investigational drug alemtuzumab for multiple sclerosis at the American Academy of Neurology's 63rd Annual Meeting in Hawaii, April 9 - 16, 2011.

8 Apr 2011

AstraZeneca's vandetanib receives FDA approval in medullary thyroid cancer

AstraZeneca today announced that the U.S. Food and Drug Administration approved the orphan drug vandetanib for the treatment of medullary thyroid cancer that cannot be removed by surgery or that has spread to other parts of the body.

7 Apr 2011

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating VB-111's potential utility as a targeted cancer treatment.

7 Apr 2011

AstraZeneca receives FDA approval for vandetanib to treat medullary thyroid cancer

The U.S. Food and Drug Administration today approved vandetanib to treat adult patients with late-stage (metastatic) medullary thyroid cancer who are ineligible for surgery and who have disease that is growing or causing symptoms.

7 Apr 2011

MEDX announces first installations of next generation T-Quest compact gamma camera

MEDX, Inc., a leading provider of nuclear medicine equipment, today introduced the next generation T-Quest™ compact gamma camera. The FDA-cleared T-Quest, includes enhanced thyroid imaging and now features expanded imaging capabilities to perform parathyroid, sentinel node, MUGA, gastric emptying, hepatobiliary, bone spots and other small organ studies.

6 Apr 2011

Asuragen launches InformThyroid, a panel of molecular markers

Asuragen, Inc. announced today the launch of Inform™Thyroid, a panel of molecular markers used on Fine Needle Aspirates (FNA) of thyroid nodules to aid physicians in the management of thyroid cancer.

6 Apr 2011

Americans concerned about thyroid cancer development from mammography

Some Americans have expressed concern, due to an erroneous media report, that the small amount of radiation a patient receives from a mammogram may significantly increase the likelihood of developing thyroid cancer. This concern simply is not supported in scientific literature.

6 Apr 2011

Life Technologies launches new TaqMan Mutation Detection Assays

Life Technologies Corporation today announced the launch of its TaqMan Mutation Detection Assays -- highly sensitive and novel molecular analysis research tools with the precision to detect a single mutant molecule hiding in a background of 1 million normal copies.

4 Apr 2011

New research: 'Good cholesterol' can act as special delivery vehicle for cancer destruction

High-density lipoprotein's hauls excess cholesterol to the liver for disposal, but new research suggests "good cholesterol" can also act as a special delivery vehicle of destruction for cancer.

1 Apr 2011

VBL's VB-111 preclinical data against metastatic cancer to be presented at AACR meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced two upcoming presentations of preclinical data from the company's VB-111 program at the American Association for Cancer Research 102nd Annual Meeting.

1 Apr 2011

Study: Thyroid hormone deficiency can affect cone opsins and colour vision

Thyroid hormone controls the eye's visual pigments throughout life. What part does the thyroid gland have in vision? Thyroid hormone is crucially involved in controlling which visual pigment is produced in the cones. Previously, it was assumed that the colour sensitivity of the cones is fixed in the adult retina.

30 Mar 2011

People of all ages and both sexes can have congestive heart failure

Elizabeth Taylor died of congestive heart failure at the age of 79 on March 23. Her death raises awareness of this serious condition that affects an estimated five million Americans.

29 Mar 2011

From fatigued to fantastic! You CAN effectively treat CFS, fatigue, fibromyalgia and muscle pain

The “perfect storm” for Fibromyalgia, CFS/ME, and fatigue in general is preparing to hit. A combination of poor nutrition, decreasing sleep, increasing stress and environmental toxins has created a human energy crisis of unprecedented proportions. Over the past 10 years, the incidence of Chronic Fatigue Syndrome (CFS) and Fibromyalgia (FMS) has exploded by 400 to 1000 percent, as documented in five separate studies. The numbers for those with CFS in the U.S., previously estimated at 500,000, are now being re-tallied at closer to 1- 2.5 million. Previous estimates placed the number of Americans with FMS at 6 million. Studies worldwide suggest this has likely gone up in the last decade to ~ 12-24 million Americans! Meanwhile, ¼ of Americans suffer with chronic pain and most are fatigued.

28 Mar 2011

New pill may protect DNA from radiation damage

The Japanese nuclear crisis has caused a surge in the demand of potassium iodide, causing shortages not only in Japan, but as far away as California, western Canada, and even southeastern Russia. Although potassium iodide does not provide generalized radiation protection because it only shields the thyroid, manufacturers and pharmacies are being bombarded with orders as the radiation hysteria mounts.

28 Mar 2011

BMY receives FDA approval for YERVOY to treat metastatic melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration approved YERVOY 3 mg/kg for the treatment of patients with unresectable or metastatic melanoma.

28 Mar 2011